NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SPRY
ARS Pharmaceuticals, Inc.
There isn't enough reported data to score SPRY yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SPRY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
SPRY's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SPRY PE Valuation
SPRY has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SPRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SPRY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SPRY on earnings quality, reporting a profit while its opponent remains loss making.
SPRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.01 | -$1.20 |
| Q2 2026 | -$2.17 | -$1.68 |
| Q1 2026 | -$2.00 | -$1.84 |
| Q4 2025 | -$1.74 | -2275% |
| Q3 2025 | -$0.81 | -$0.30 |
| Q2 2025 | -$0.49 | -$0.02 |
| Q1 2025 | -$0.16 | +$0.36 |
| Q4 2024 | $0.08 | +$0.65 |
SPRY is still losing money, but less than at its worst: $2.01 per share over the past year, against $2.72 at its worst in early 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SPRY on profitability, with a higher operating margin.
SPRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.7M | +16% |
| Q2 2026 | $33.7M | +114% |
| Q1 2026 | $22.7M | +184% |
| Q4 2025 | $28.1M | -68% |
| Q3 2025 | $32.5M | +1472% |
| Q2 2025 | $15.7M | +3043% |
| Q2 2024 | $500K | +4900% |
SPRY's revenue is recovering but still below its 2024 peak: $38M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +73 points |
| Q2 2026 | -183% | +120 points |
| Q1 2026 | -265% | +201 points |
| Q4 2025 | -148% | -202 points |
| Q3 2025 | -164% | +888 points |
| Q2 2025 | -303% | +2765 points |
| Q1 2025 | -466% | N/A |
| Q4 2024 | 55% | N/A |
SPRY's operating margin was −91% last quarter, up 73 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SPRY on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | +$13.5M |
| Q2 2026 | -$60.9M | -$21.3M |
| Q1 2026 | -$44.9M | -$4.1M |
| Q4 2025 | -$43.5M | -204% |
| Q3 2025 | -$47.2M | -$32.6M |
| Q2 2025 | -$39.6M | -$32.3M |
| Q1 2025 | -$40.8M | -$34M |
| Q4 2024 | $41.7M | +$59M |
SPRY has burned cash in almost every quarter: −$183M over the past year, against −$86M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SPRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SPRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +373K shares |
| 1 year | +0.9% | +878K shares |
| 3 years | +4.3% | +4.1M shares |
| 5 years | +186% | +64.8M shares |
| Available history | +201% | +66.6M shares |
SPRY has 100M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SPRY Net Leverage
SPRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SPRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 14.3 | Oversold |
SPRY's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SPRY PE vs Healthcare Sector
| Metric | SPRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SPRY has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SPRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.80 | 0.3% above |
| 20 week MA | $5.13 | 26% below |
| 50 week MA | $7.64 | 50% below |
| 100 week MA | $10.2 | 63% below |
| 200 week MA | $9.31 | 59% below |
SPRY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SPRY on returns for 2026, with the stronger performance.
SPRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.0 | $35.8 | +43% |
| 2021 | $35.8 | $6.65 | -81% |
| 2022 | $6.65 | $8.08 | +22% |
| 2023 | $8.08 | $5.48 | -32% |
| 2024 | $5.48 | $10.8 | +97% |
| 2025 | $10.8 | $11.4 | +5.5% |
| 2026 YTD | $11.4 | $3.81 | -67% |
SPRY is down 67% so far in 2026, after finishing higher in four of the previous six years.